The new contract comes after the company collaborated with the NIH for the launch of the MaximBio ClearDetect Covid-19 Antigen Home Test. Credit: Maxim Biomedical / PRNewswire.

Diagnostic solutions manufacturer MaximBio has received a new contract from the National Institutes of Health (NIH) for the development of a Covid-19 and Influenza A/B combo test.

The contract was awarded under the NIH’s Rapid Acceleration of Diagnostics (RADx) initiative, which was established to encourage organisations to speed up innovation in the development, commercialisation and implementation of diagnostic technologies for Covid-19 testing.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new contract agreement builds on MaximBio’s collaboration with the NIH during the peak of the Covid-19 pandemic.

It is partially funded by the National Institute of Biomedical Imaging and Bioengineering, the NIH and the Department of Health and Human Services.

The company previously collaborated with the NIH to successfully launch the MaximBio ClearDetect Covid-19 Antigen Home Test.

See Also:

The new Covid-19 and Influenza A/B combo test will use innovative lateral-flow assay (LFA) technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

When combined with the FiarFly analyser platform and MaximBio’s manufacturing techniques, the LFA technology enables enhanced assay performance.

The FiarFly platform comprises a pocket-sized, battery-powered reader designed to bring diagnostic testing closer to the patient.

It provides performance similar to the lab but in the comfort of a home and in a cost-effective manner.

The easy-to-operate reader enables increased accessibility and provides results with higher sensitivity at a cost similar to visually read at-home tests.

The platform can be used to perform several tests on a single device. It comes with Health Insurance Portability and Accountability Act-compliant connectivity for reporting electronic medical record results.

In a recent interview, MaximBio chief operating officer Jonathan Maa stated that the new collaboration is backed by the company’s earlier success with RADx and expanded manufacturing capabilities in the US.

Maa said: “Our upgraded infrastructure allows us to produce in excess of 100 million tests annually, right here in the United States.

“We are looking forward to working again with the NIH on this exciting new project and the opportunity to offer the market an innovative, yet affordable, diagnostic platform to transform the future of at-home testing solutions.”